MHRA July 2019

https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-emerade-150-300-and-500-microgram-solution-for-injection-in-pre-filled-syringe-mdr-55-06-18

From Queens Bower –

The MHRA reported a risk of Emerade adrenaline product failing to deliver a dose of adrenaline from the syringe due to blockage of the needle.
However, if the patient follows the existing advice to carry two in-date pens with them at all times, the risk of not being able to deliver a dose of adrenaline before the emergency services arrive is substantially reduced (from 0.23% to 0.000529%).

 

Comments are closed.